
Recent findings on the role of wild-type and mutant p53 in cancer ...
R175H and R273H are more prone to aggregation than wild-type (WT) p53, and their pathological aggregation can lead to various cancers. A recent study investigated the dynamic and structural properties of the R175H and R273H mutants in the p53 core domain (p53C) using extensive all-atom molecular dynamics simulations.
Upregulation of wild-type p53 by small molecule-induced
May 25, 2021 · Here, we reported that a new quinolone compound RYL-687 significantly inhibited non-small cell lung cancer (NSCLC) cells which express wild type (wt) p53, in contract to its much weaker...
Wt p53 impairs response to chemotherapy: make lemonade to …
Jul 13, 2012 · As published recently in Cancer Cell, p53 impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. I discuss that, while treating tumors lacking wt p53, this phenomenon can be exploited to protect normal cells from chemotherapy because all normal cells have wt p53.
Understanding the complexity of p53 in a new era of tumor …
May 9, 2024 · Here, we review the complexity of different layers of p53 regulation, and the recent advance of the p53 pathway in metabolism, ferroptosis, immunity, and others that contribute to tumor suppression.
The p53 Pathway in Glioblastoma - PMC
The high prevalence and expression of p53 mutations in GBM makes them an important target for precision medicine therapies. Reactivating or restoring wt-p53 would be a promising therapy for many cancers. Various strategies have been explored to induce/reactivate wt-p53 or inhibit GOF mut-p53 in a wide range of cancer types, including GBM .
p53: A tale of complexity and context - Cell Press
Mar 28, 2024 · Bottom: wild-type (WT) p53 helps maintain metabolic homeostasis and genome integrity and restrains cancer-associated processes, thereby suppressing tumorigenesis.
Wild-type p53 oligomerizes more efficiently than p53 hot-spot …
Aug 8, 2018 · Single residue changes, caused by hot-spot mutations of the TP53 gene in human cancer, transform wild-type (wt) p53 tumor suppressor proteins into potent oncoproteins - with gain-of-function, tumor-promoting activity.
The deubiquitinase inhibitor WP1130 drives nuclear aggregation …
6 days ago · Mutp53 inhibits the transactivation function of WT p53 by exerting a dominant-negative effect. Therefore, we hypothesize that WP1130 treatment may cause ubiquitinated mutp53 to undergo nuclear aggregation and proteasomal degradation, while the mutp53 that forms an adduct with WP1130 adopts a WT-like conformation. This shift toward the folded ...
p53 activates circASCC3 to repress R-loops and enhance ... - PNAS
In contrast, knockdown of p53 using two independent siRNAs significantly reduced the expression of circASCC3 and ASCC3 in cancer cells when treated with Cisplatin or Nutlin-3 (Fig. 2 E–G and SI Appendix, Fig. S2 B–D). We also tested whether WT p53 was required for this regulation by employing cancer cells without p53 or expressing a mutant p53.
Suppression of stress granule formation is a vulnerability imposed …
Mar 10, 2025 · To test this hypothesis, we knocked down mutp53 in Huh7 (p53 Y220C), SNU449 (p53 A161T), and HepG2 (p53 wt) HCC cells (Fig. 1b and Supplementary Fig. S1b–d), or overexpressed p53 R175H-3XFLAG in ...